Perioperative intratumoral administration of cisplatin for treatment of cutaneous tumors in equidae.
Twenty-seven horses (and 1 mule) with 32 histologically confirmed cutaneous tumors were studied to evaluate the effects of intratumoral injection of cisplatin initiated at the time of surgery. As a result of surgery, 9 of the wounds were closed primarily (5 sarcoids, 4 carcinomas) and 23 were left open to granulate (16 sarcoids, 6 carcinomas, 1 hamartoma). Chemotherapy consisted of 4 treatment sessions of intratumoral injection of cisplatin in purified sesame oil at 2-week intervals. The first treatment session was administered intraoperatively. A controlled-release formulation of cisplatin in sesame oil was used to limit drug egress from the injection site. Dosage was 1 mg of cisplatin/cm3 of tissue. The mean relapse-free interval was 41 +/- 3.7 months. The estimates of overall relapse-free survival rates were 92 +/- 5% at 1 year and 77 +/- 11% at 4 years. Cisplatin-related local toxicosis was minimal and wound healing was not compromised. Intratumoral injection of cisplatin appears safe and effective when administered in the perioperative period for selected tumors in equidae.
Théon
A P
AP
Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California, Davis 95616-8745.
Pascoe
J R
JR
Meagher
D M
DM
D000818:Animals; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000601:surgery / Q000662:veterinary*; D002945:Cisplatin / Q000008:administration & dosage* / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D004655:Emulsions; D018397:Equidae; D005260:Female; D005500:Follow-Up Studies; D006734:Horse Diseases / Q000188:drug therapy* / Q000601:surgery; D006736:Horses; D015552:Injections, Intralesional; D007430:Intraoperative Care / Q000662:veterinary; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control / Q000662:veterinary; D012878:Skin Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000662:veterinary*; D016896:Treatment Outcome
D003692:Delayed-Action Preparations; D004655:Emulsions; D002945:Cisplatin